Entrada Therapeutics Highlights Mantarray Data at Frontiers in Myogenesis Conference 2023

Entrada Therapeutics featured recent data that was generated on the Mantarray platform at the Frontiers in Myogenesis Conference. The poster presentation concludes:

  • Consistent with previous studies in 2D cultures and animal models, these findings demonstrate the ability of the EEV™ platform to efficiently deliver exon skipping oligonucleotides to 3D-engineered skeletal muscle tissues.

  • Dystrophin protein was observed in EMTs [engineered muscle tissues] treated with EEV-PMO44 as early as 7 days post-washout, detectable for at least 6-weeks post-washout, and localized correctly to the sarcolemma.

  • This 3D organoid system allowed us [Entrada] to demonstrate EEV-PMO construct efficacy and long-term duration of effect, underscoring the utility of this 3D culture system for the drug development process in Duchenne muscular dystrophy.

Below are a couple figures from the poster. View the full poster here on Entrada Therapeutics’ website.

This data represents an encouraging step for the use of 3D engineered muscle tissues in drug discovery.

Cross-sectional images (40× cropped) of EMTs demonstrating proper dystrophin expression on sarcolemma.

Longitudinal images (40× cropped) of EMTs, demonstrating proper dystrophin expression on sarcolemma.

Arianna Kieser